-
Stocks sink, yields at multi-decade highs and oil spikes on Mideast flare-up
-
US aircraft carrier approaches Thai port after months at sea
-
US defends Trump Venezuela oil deal as energy secretary lands in Caracas
-
Nepal's young PM faces gravest test after flood catastrophe
-
Jubilant Monfils celebrates birthday with US Open win
-
What rainbow? LGBTQ Indonesians on edge as hostility mounts
-
The Japanese idealist behind the last deradicalisation NGO in Somalia
-
O'Connor eyes Wallabies World Cup swansong after Force return
-
Rybakina, Gauff advance as Zverev launches US Open campaign
-
Syria UXO causing death, injury every six hours: charity
-
Macron in Britain to help unveil tapestry, hold Burnham talks
-
Tiger Woods set to change not guilty plea in DUI case: court documents
-
China's Xi to hold talks with Sisi in rare visit to Egypt
-
Zelensky warns airlines Russian skies not safe due to Ukraine drones
-
Confident Gauff reaches US Open 2nd round with straight-set win
-
UK vows anti-settler measures as Israel warns of retaliation
-
US postal whistleblower warns ballot system could disrupt midterms
-
New pro Koivun among US Presidents Cup picks
-
John Ternus takes over as Apple enters era of AI, foldable phones
-
G20 finance leaders close talks marked by US welcoming Russia
-
Second-ranked Rybakina eases into US Open 2nd round
-
From Hollywood to big time tennis: teen makes US Open debut
-
Man City sign Fernandez, Ndiaye as Premier League clubs set new spending record
-
Man City secure Premier League record deal to sign Fernandez
-
Alcaraz aims to step it up in round two of US Open title defense
-
Kaepernick says NFL 'blackballing me' decade after protest
-
Honduran judge drops corruption charges against ex-leader Hernandez
-
Atletico loan David from Juve, send Lemar to Elche
-
Mudryk joins Spurs on loan from Chelsea after doping ban ends
-
Chelsea 'keeper Sanchez makes deadline-day move to Como
-
What's next after judge strikes down New York's landmark climate fund law
-
Kroenke to buy baseball's Los Angeles Angels: statement
-
Cobolli claws out five-set victory at rain-hit US Open
-
US defends Trump's Venezuela oil deal
-
Ndiaye seizes 'chance of a lifetime' in Man City move
-
OpenAI to launch new model with 'stronger safeguards' after hack
-
Global bond sell-off, surging oil prices send markets into the red
-
Fans mourn 'bittersweet' final Ariana Grande gig in London
-
Zuckerberg, Musk make plea at G20 for more AI data centers
-
Norway's King Haakon VIII swears allegiance to constitution
-
'Discomfort' at G20 finance talks as US hosts Russian minister
-
Syria site infrastructure 'consistent with nuclear reactor': IAEA
-
Man City set to sign Fernandez for record fee, Ndiaye on deadline day
-
Juventus sign Woltemade, Sarr on loan from Premier League
-
Back-to-school in Cuba a grim day with shortages of everything
-
US strikes Iran in latest tit-for-tat attacks
-
Canadian minister says Russia's G20 presence sparked 'discomfort'
-
China's Xi arrives in Egypt as US sanctions threat looms over Iran links
-
IMF reaches agreement with Senegal on new $2.2 bn loan programme
-
Car bomb at Colombian police station kills one, injures 11
Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") announced today that warrant exchanges and exercises over the last four trading days have generated $3.1 million in cash. The proceeds will fund working-capital needs and advance the Company's peptide-based drug candidates for stress-related and central-nervous-system disorders.
This financing comes as Protagenic executes on its previously announced business combination with Phytanix Bio Inc. (May 19, 2025). The combination has brought together six complementary drug programs spanning stress disorders, epilepsy, obesity, and other indications under one company.
About Protagenic Therapeutics, Inc.
Protagenic Therapeutics (Nasdaq: PTIX) is pioneering peptides for stress-related disorders. For more information, visit www.protagenic.com.
About Phytanix Bio Inc.
Phytanix Bio is an innovative pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and "cannabinoid-like" molecules. For more information, visit www.phytanix.com.
Forward-Looking Statements:
This press release contains forward-looking statements concerning Protagenic Therapeutics' product candidates and clinical trial plans. These statements are subject to various risks and uncertainties. Investors are urged to exercise caution and not place undue reliance on these forward-looking statements.
Company Contact:
Alexander K. Arrow, MD, CFA
Chief Financial Officer
Protagenic Therapeutics, Inc.
149 Fifth Ave, Suite 500, New York, NY 10010
Tel: 213-260-4342
Email: [email protected]
SOURCE: Protagenic Therapeutics, Inc.
View the original press release on ACCESS Newswire
G.P.Martin--AT